GT201000184A - Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
GT201000184A
GT201000184A GT201000184A GT201000184A GT201000184A GT 201000184 A GT201000184 A GT 201000184A GT 201000184 A GT201000184 A GT 201000184A GT 201000184 A GT201000184 A GT 201000184A GT 201000184 A GT201000184 A GT 201000184A
Authority
GT
Guatemala
Prior art keywords
mercaptociclopentanocarboxílico
acid
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
GT201000184A
Other languages
English (en)
Inventor
Gloanec Philippe
De Nanteuil Guillaume
Parmentier Jean-Gilles
Guillouzic Anne-Francoise
Verbeuren Tony
Rupin Alain
Mennecier Philippe
Vallez Marie-Odile
Quirion Jean-Charles
Jubault Philippe
Boyer Nicolas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000184A publication Critical patent/GT201000184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS DERIVADOS DE ÁCIDO-2-MERCAPTOCICLOPENTANOCARBOXÍLICO, SU USO EN ASOCIACIÓN CON UN FIBRINOLÍTICO, UN ANTICOAGULANTE O UN ANTIPLAQUETARIO, PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN. ESTOS COMPUESTOS SON INHIBIDORES DE TAFIA (INHIBIDOR DE LA FIBRINOLISIS ACTIVABLE POR TROMBINA ACTIVADO).
GT201000184A 2009-06-26 2010-06-18 Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen GT201000184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903111A FR2947266B1 (fr) 2009-06-26 2009-06-26 Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
GT201000184A true GT201000184A (es) 2012-04-30

Family

ID=41594318

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000184A GT201000184A (es) 2009-06-26 2010-06-18 Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (28)

Country Link
US (1) US8309341B2 (es)
EP (1) EP2272826A1 (es)
JP (1) JP5238757B2 (es)
KR (1) KR101187394B1 (es)
CN (1) CN101928241A (es)
AP (1) AP2010005304A0 (es)
AR (1) AR078415A1 (es)
AU (1) AU2010202563A1 (es)
BR (1) BRPI1001935A2 (es)
CA (1) CA2707647A1 (es)
CL (1) CL2010000694A1 (es)
CO (1) CO6300113A1 (es)
CR (1) CR11494A (es)
CU (1) CU20100133A7 (es)
EA (1) EA017867B1 (es)
EC (1) ECSP10010292A (es)
FR (1) FR2947266B1 (es)
GT (1) GT201000184A (es)
IL (1) IL206405A0 (es)
MA (1) MA32340B1 (es)
MX (1) MX2010007070A (es)
NI (1) NI201000111A (es)
NZ (1) NZ586444A (es)
PE (1) PE20110022A1 (es)
TW (1) TWI380813B (es)
UY (1) UY32702A (es)
WO (1) WO2010149888A1 (es)
ZA (1) ZA201004398B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109467506B (zh) * 2017-09-07 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
US4385062A (en) * 1980-01-09 1983-05-24 Gruppo Lepetit S.P.A. 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents
JPS5750955A (en) * 1980-09-12 1982-03-25 Hokko Chem Ind Co Ltd Oxime carbamate derivative and insecticide
JPH0565258A (ja) * 1991-07-03 1993-03-19 Nippon Bayeragrochem Kk 酢酸アニリド誘導体および除草剤
PL175475B1 (pl) * 1992-05-29 1999-01-29 Procter & Gamble Pharma Nowe zawierające siarkę związki fosfonianowe
PT1311488E (pt) * 2000-08-17 2009-12-30 Pfizer Ltd Imidazóis substituídos utilizados como inibidores de tafia
US7528173B2 (en) * 2002-03-21 2009-05-05 Schering Aktiengesellshaft Plasma carboxypeptidase B inhibitors
US7718406B2 (en) * 2002-10-04 2010-05-18 Dsm Ip Assets B.V. Substrates for TAFI (A)
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
NZ586444A (en) 2011-09-30
US8309341B2 (en) 2012-11-13
EP2272826A1 (fr) 2011-01-12
NI201000111A (es) 2010-12-17
CN101928241A (zh) 2010-12-29
CR11494A (es) 2010-09-13
CO6300113A1 (es) 2011-07-21
CU20100133A7 (es) 2012-02-15
CL2010000694A1 (es) 2011-05-06
ECSP10010292A (es) 2011-06-30
BRPI1001935A2 (pt) 2012-03-06
KR20110000516A (ko) 2011-01-03
ZA201004398B (en) 2011-03-30
JP2011006416A (ja) 2011-01-13
FR2947266B1 (fr) 2011-06-17
US20100330064A1 (en) 2010-12-30
EA017867B1 (ru) 2013-03-29
IL206405A0 (en) 2010-12-30
TW201105322A (en) 2011-02-16
JP5238757B2 (ja) 2013-07-17
AU2010202563A1 (en) 2011-01-20
KR101187394B1 (ko) 2012-10-02
MX2010007070A (es) 2011-01-05
WO2010149888A1 (fr) 2010-12-29
PE20110022A1 (es) 2011-02-04
TWI380813B (zh) 2013-01-01
CA2707647A1 (fr) 2010-12-26
AP2010005304A0 (en) 2010-06-30
MA32340B1 (fr) 2011-06-01
FR2947266A1 (fr) 2010-12-31
EA201000867A1 (ru) 2010-12-30
UY32702A (es) 2010-12-31
AR078415A1 (es) 2011-11-09

Similar Documents

Publication Publication Date Title
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
EA201170772A1 (ru) Органические соединения
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
EA200970156A1 (ru) Пиридизиноновые производные
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
EA201070278A1 (ru) Ингибиторы гамма-секретазы
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
PA8792401A1 (es) Fenilendiaminas
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR064123A1 (es) Derivados cristalinos de azetidina. procesos de obtencion y usos.
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.